Lungenkarzinom

详细信息    查看全文

• 作者：A. Schultheis ; J. Wolf ; R. Büttner
• 关键词：Nichtkleinzelliges Bronchialkarzinom ; Immunsystem ; Tumorimmuntherapie ; Personalisierte Medizin ; Biomarker ; Carcinoma ; non ; small cell lung ; Immune system ; Cancer immunotherapy ; Personalized medicine ; Biomarkers
• 刊名：Wiener klinisches Magazin
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：17
• 期：4
• 页码：14-21
• 全文大小：455 KB
• 参考文献：1. Macconaill LE (2012) Advancing personalized cancer medicine in lung cancer. Arch Pathol Lab Med 136:1210-216 CrossRef
  2. Molina JR et?al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584-94 CrossRef
  3. Schiller JH et?al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N?Engl J Med 346:92-8
  4. Sandler A et?al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N?Engl J Med 355:2542-550
  5. Shepherd FA et?al (2005) Erlotinib in previously treated non-small-cell lung cancer. N?Engl J Med 353:123-32
  6. Mok TS et?al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N?Engl J Med 361:947-57
  7. Rosell R et?al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N?Engl J Med 361:958-67
  8. Kwak EL et?al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N?Engl J Med 363:1693-703
  9. Sequist LV et?al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26 CrossRef
  10. Topalian SL, Weiner GJ, Pardoll DM (2011) Cancer immunotherapy comes of age. J?Clin Oncol 29:4828-836
  11. Finn OJ (2008) Cancer immunology. N?Engl J Med 358:2704-715
  12. Murala S et?al (2010) Current status of immunotherapy for the treatment of lung cancer. J?Thorac Dis 2:237-44
  13. Thomas A, Hassan R (2012) Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 13:e301–e310 CrossRef
  14. Poschke I, Mougiakakos D, Kiessling R (2011) Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 60:1161-171 CrossRef
  15. Reck M (2012) What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol 23(Suppl?8):viii28–viii34
  16. Topalian SL et?al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N?Engl J Med 366:2443-454
  17. Brahmer JR et?al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N?Engl J Med 366:2455-465
  18. Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207-12 j.coi.2011.12.009" target="_blank" title="It opens in new window">CrossRef
  19. Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1:220-28 CrossRef
  20. Spadaro M et?al (2008) Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB?J 22:2747-757 j.07-098038" target="_blank" title="It opens in new window">CrossRef
  21. Digumarti R et?al (2011) A randomized, double-blind, placebo-controlled, phase?II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J?Thorac Oncol 6:1098-103
  22. Hayes TG et?al (2006) Phase?I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 24:233-40 CrossRef
  23. Parikh PM et?al (2011) Randomized, double-blind, placebo-controlled phase?II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J?Clin Oncol 29:4129-136
  24. Butts C et?al (2005) Randomized phase?IIB trial of BLP25 liposome vaccine in stage?IIIB and?IV non-small-cell lung cancer. J?Clin Oncol 23:6674-681
  25. Nemunaitis J et?al (2006) Phase?II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J?Clin Oncol 24:4721-730
  26. Nemunaitis J et?al (2009) Phase?II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 16:620-24 CrossRef
  27. Kong F et?al (1999) Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86:1712-719 CrossRef
  28. Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014-021 j.1349-7006.2009.01303.x" target="_blank" title="It opens in new window">CrossRef
  29. Bolli M et?al (2002) Tissue microarray evaluation of Melanoma antigen?E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236:785-93 CrossRef
  30. Atanackovic D et?al (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U?S?A 105:1650-655 CrossRef
  31. Atanackovic D et?al (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J?Immunol 172:3289-296
  32. Grah J et?al (2008) Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Coll Antropol 32:731-36
  
• 作者单位：A. Schultheis (1)
  J. Wolf (2)
  R. Büttner (1)
  
  1. Institut für Pathologie, CIO K?ln Bonn, Universit?tsklinikum K?ln, Kerpener Str. 62, 50937, K?ln, Deutschland
  2. Klinik für Innere Medizin I, CIO K?ln Bonn, Universit?tsklinikum K?ln, Kerpener Str. 62, 50937, K?ln, Deutschland
  
• ISSN：1613-7817

文摘

Recent advances in the treatment of non-small cell lung cancer (NSCLC) are based on the identification of so-called driver mutations, resulting in a more personalized treatment setting. Currently about 15?% of NSCLC patients benefit from improved treatment protocols based on the genetic background of the tumor. In the last few years cancer immunotherapy has returned to the center of attention and comprises a variety of treatment approaches incorporating adaptive, as well as innate immunity. Current strategies involve the use of monoclonal antitumor antibodies, cancer vaccines, adoptive transfer of ex vivo activated T and NK cells as well as the blockade of so-called immune checkpoints (immune inhibitory pathways). Especially the combination of current treatments with immunotherapy seems promising to achieve highly potent antitumor effects. However, a profound understanding of the dynamic and complex interaction between lung cancer and the host immune system and especially its immune checkpoints is the foundation to identify potential biomarkers for a personalized cancer immunotherapy approach.